טוען...

Phase I Study of Vincristine, Irinotecan, and (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial

PURPOSE: (131)I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical with activity in patients with relapsed or refractory neuroblastoma. Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG toget...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Clin Cancer Res
Main Authors:	DuBois, Steven G., Chesler, Louis, Groshen, Susan, Hawkins, Randall, Goodarzian, Fariba, Shimada, Hiroyuki, Yanik, Greg, Tagen, Michael, Stewart, Clinton, Mosse, Yael P., Maris, John M., Tsao-Wei, Denice, Marachelian, Araz, Villablanca, Judith G., Matthay, Katherine K.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	2012
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6814395/ https://ncbi.nlm.nih.gov/pubmed/22421195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3201
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Phase I Study of Vincristine, Irinotecan, and (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial

פריטים דומים